Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel in New York City.
Company President and CEO Dror Bashan will deliver a presentation on Wednesday, September 11, at 12:30 p.m. EDT in the Holmes II Room on the Fourth floor. The management team will also engage in one-on-one meetings with registered investors throughout the conference.
Protalix is known for its proprietary ProCellEx® plant cell-based protein expression system, which is used in the development and production of recombinant therapeutic proteins.
Protalix BioTherapeutics (NYSE American: PLX), una società biofarmaceutica specializzata in proteine terapeutiche ricombinanti, ha annunciato la sua partecipazione alla 26ª Conferenza Globale Annuale sugli Investimenti H.C. Wainwright. L'evento si terrà dal 9 all'11 settembre 2024, presso il Lotte New York Palace Hotel di New York City.
Il Presidente e CEO della società, Dror Bashan, terrà una presentazione mercoledì 11 settembre, alle 12:30 EDT nella Sala Holmes II al quarto piano. Il team di gestione parteciperà anche a incontri individuali con investitori registrati durante tutta la conferenza.
Protalix è nota per il suo sistema di espressione proteica a base di cellule vegetali ProCellEx®, utilizzato nello sviluppo e produzione di proteine terapeutiche ricombinanti.
Protalix BioTherapeutics (NYSE American: PLX), una compañía biofarmacéutica especializada en proteínas terapéuticas recombinantes, ha anunciado su participación en la 26ª Conferencia Global Anual de Inversiones H.C. Wainwright. El evento está programado para el 9 al 11 de septiembre de 2024, en el Lotte New York Palace Hotel en la ciudad de Nueva York.
El Presidente y CEO de la compañía, Dror Bashan, ofrecerá una presentación el miércoles 11 de septiembre a las 12:30 p.m. EDT en la Sala Holmes II en el cuarto piso. El equipo de gestión también participará en reuniones individuales con inversores registrados a lo largo de la conferencia.
Protalix es conocida por su sistema propietario de expresión de proteínas a base de células vegetales ProCellEx®, que se utiliza en el desarrollo y producción de proteínas terapéuticas recombinantes.
Protalix BioTherapeutics (NYSE American: PLX)는 재조합 치료 단백질을 전문으로 하는 생명공학 회사로서, H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일에서 11일 사이에 뉴욕시의 롯데 뉴욕 팰리스 호텔에서 열릴 예정입니다.
회사의 대표이사인 Dror Bashan은 9월 11일 수요일 오후 12시 30분 EDT에 4층의 홀름스 II 룸에서 발표를 할 예정입니다. 경영진 팀은 이 회의 동안 등록된 투자자들과의 일대일 미팅에도 참여할 것입니다.
Protalix는 재조합 치료 단백질의 개발 및 생산에 사용되는 ProCellEx® 식물 세포 기반 단백질 발현 시스템으로 잘 알려져 있습니다.
Protalix BioTherapeutics (NYSE American: PLX), une entreprise biopharmaceutique spécialisée dans les protéines thérapeutiques recombinantes, a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. L'événement est prévu du 9 au 11 septembre 2024, au Lotte New York Palace Hotel à New York.
Le Président et PDG de l'entreprise, Dror Bashan, donnera une présentation le mercredi 11 septembre à 12h30 EDT dans la salle Holmes II au quatrième étage. L'équipe de direction participera également à des réunions individuelles avec des investisseurs enregistrés tout au long de la conférence.
Protalix est connu pour son système d'expression protéique à base de cellules végétales ProCellEx®, utilisé dans le développement et la production de protéines thérapeutiques recombinantes.
Protalix BioTherapeutics (NYSE American: PLX), ein biopharmazeutisches Unternehmen, das auf rekombinante therapeutische Proteine spezialisiert ist, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright angekündigt. Die Veranstaltung findet vom 9. bis 11. September 2024 im Lotte New York Palace Hotel in New York City statt.
Der Präsident und CEO des Unternehmens, Dror Bashan, wird am 11. September, um 12:30 Uhr EDT eine Präsentation im Holmes II Raum im vierten Stock halten. Das Management-Team wird außerdem Einzelgespräche mit registrierten Investoren während der gesamten Konferenz führen.
Protalix ist bekannt für sein proprietäres ProCellEx® Pflanzenzellsystem zur Proteinexpression, das bei der Entwicklung und Produktion von rekombinanten therapeutischen Proteinen eingesetzt wird.
- None.
- None.
CARMIEL,
Mr. Bashan will present on Wednesday, September 11, at 12:30 p.m. Eastern Daylight Time (EDT) in the Holmes II Room, Fourth floor. Management will participate in one-on-one meetings throughout the conference with registered investor attendees.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long action DNase I for the treatment of NETs–related diseases; and others.
Investor Contact
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Logo - https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-present-at-the-hc-wainwright-26th-annual-global-investment-conference-302237774.html
SOURCE Protalix BioTherapeutics, Inc.
FAQ
When and where is Protalix BioTherapeutics (PLX) presenting at the H.C. Wainwright conference?
What is the date range for the H.C. Wainwright 26th Annual Global Investment Conference?
Who will be representing Protalix BioTherapeutics (PLX) at the H.C. Wainwright conference?
What type of meetings will Protalix BioTherapeutics (PLX) management participate in during the conference?
What is Protalix BioTherapeutics' (PLX) main focus as a biopharmaceutical company?
